Jump to content

Pancreatic islets

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Vokesk (talk | contribs) at 18:46, 23 April 2012 (→‎Anatomy and Histology). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Template:Distinguish2

Islets of Langerhans
Islet of Langerhans (mouse) in its typical proximity to a blood vessel; insulin in red, nuclei in blue.
Islets of Langerhans, hemalum-eosin stain.
Details
Identifiers
Latininsulae pancreaticae
MeSHD007515
TA98A05.9.01.019
TA23128
FMA16016
Anatomical terminology
File:Mouse islet LM SolimenaLab.jpg
This photograph shows a mouse pancreatic islet, an often spherical group of hormone-producing cells. Insulin is labelled here in green, glucagon in red, and the nuclei in blue.
The diagram shows the structural differences between rat islets (top) and humans islets (bottom) as well as the ventral part (left) and the dorsal part (right) of the pancreas. Different cell types are colour coded. Rodent islets, unlike the human ones, show the characteristic insulin core.
File:Islet.png
A porcine islet of Langerhans. The left image is a brightfield image created using hematoxylin stain; nuclei are dark circles and the acinar pancreatic tissue is darker than the islet tissue. The right image is the same section stained by immunofluorescence against insulin, indicating beta cells.

The islets of Langerhans are the regions of the pancreas that contain its endocrine (i.e., hormone-producing) cells. Discovered in 1869 by German pathological anatomist Paul Langerhans at the age of 22,[1] the islets of Langerhans constitute approximately 1 to 2% of the mass of the pancreas

Anatomy and Histology

There are about one million islets distributed throughout the pancreas of a healthy adult human,[2]:914 each of which measures about 0.2 mm in diameter.[2]:914 Each is separated from the surrounding pancreatic tissue by a thin fibrous connective tissue capsule which is continuous with the fibrous connective tissue that is interwoven throughout the rest of the pancreas.[2]:914 The combined mass of the islets is 1 to 1.5 grams.

Cell types

Hormones produced in the islets of Langerhans are secreted directly into the blood flow by (at least) five different types of cells. In rat islets, endocrine cell subsets are distributed as follows:[3]

It has been recognized that the cytoarchitecture of pancreatic islets differs between species.[4][5][6] In particular, while rodent islets are characterized by a predominant proportion of insulin-producing beta cells in the core of the cluster and by scarce alpha, delta and PP cells in the periphery, human islets display alpha and beta cells in close relationship with each other throughout the cluster.[4][6]

Islets can influence each other through paracrine and autocrine communication, and beta cells are coupled electrically to other beta cells (but not to other cell types).

Paracrine feedback

The paracrine feedback system of the islets of Langerhans has the following structure:[7]

  • Insulin: activates beta cells and inhibits alpha cells
  • Glucagon: activates alpha cells which activates beta cells and delta cells
  • Somatostatin: inhibits alpha cells and beta cells

Electrical activity

Electrical activity of pancreatic islets has been studied using patch clamp techniques, and it has turned out that the behavior of cells in intact islets differs significantly from the behavior of dispersed cells.[8]

Islet transplantation as a treatment for type 1 diabetes

Islet cell transplantation has the possibility of restoring beta cell function from diabetes, offering an alternative to a complete pancreas transplantation or an artificial pancreas.

Because the beta cells in the islets of Langerhans are selectively destroyed by an autoimmune process in type 1 diabetes, clinicians and researchers are actively pursuing islet transplantation as a means of restoring physiological beta cell function in patients with type 1 diabetes.[9][10]

Recent clinical trials have shown that insulin independence and improved metabolic control can be reproducibly obtained after transplantation of cadaveric donor islets into patients with unstable type 1 diabetes.[10]

Islet transplantation for type 1 diabetes currently requires potent immunosuppression to prevent host rejection of donor islets.[11]

An alternative source of beta cells, such insulin-producing cells derived from adult stem cells or progenitor cells would contribute to overcoming the current shortage of donor organs for transplantation. The field of regenerative medicine is rapidly evolving and offers great hope for the nearest future. However, type 1 diabetes is the result of the autoimmune destruction of beta cells in the pancreas. Therefore, an effective cure will require a sequential, integrated approach that combines adequate and safe immune interventions with beta cell regenerative approaches.[12]

Another potential source of beta cells may be xenotransplantation. The most likely source for xenogeneic islets for transplantation into human currently under evaluation is the pig pancreas. Interestingly, human and porcine insulin differ only for one aminoacid, and insulin extracted from porcine pancreata has been used for the treatment of patients with diabetes before the development of recombinant human insulin technology. Several studies in small and large animals models have shown that transplantation of islet cells across species is possible. However, several problems need to be overcome for porcine islet transplantation to become a viable clinical option. The immunogenicity of xenogeneic tissues may be different from and even stronger than allogeneic tissues. For instance, Galalpha1-3Galbeta1-4GlcNAc (alpha galactosidase, alpha-Gal) expressed on porcine cells represents a major barrier to xenotransplantation being the target of preformed antibodies present in human blood. Remarkable progress has been recorded in the development of genetically modified pigs lacking or overexpressing molecules that may improve acceptance of transplanted tissues across into humans. Pigs lacking alpha-Gal or overexpressing human Decay Accelerating Factor (hDAF), amongst others, have been generated to study the impact on transplanted outcome in nonhuman primate models. Another possible antigenic target is the Hanganutziu-Deichter antigen, a sialic acid found in pigs and not humans, which may contribute to immunogenicity of porcine islets. Another limitation is the risk for transmission of zoonotic infections from pigs to humans, particularly from Porcine Endogenous Retro-Viruses (PERV). Amongst the approaches proposed to overcome islet xenorejection is immunoisolation of the clusters using encapsulation techniques that may shield them from immune attack. Studies in rodents and large animals have shown great promise that justify cautious optimism for the near future. Nonrandomized, uncontrolled pilot clinical trials are current ongoing in subject with insulin-requiring diabetes to test the efficacy of encapsulation techniques to protect xenogeneic islets in the absence of chronic anti-rejection drugs.

Gallery

  • Hormones/islet architecture
  • Mouse islet immunostained for pancreatic polypeptide
    Mouse islet immunostained for pancreatic polypeptide
  • Mouse islet immunostained for insulin
    Mouse islet immunostained for insulin
  • Mouse islet immunostained for glucagon
    Mouse islet immunostained for glucagon
  • Illustration of dog pancreas. 250x.
    Illustration of dog pancreas. 250x.

See also

References

  1. ^ Langerhans P (1869). "Beitrage zur mikroscopischen anatomie der bauchspeichel druse". Inaugural-dissertation. Berlin: Gustav Lange.
  2. ^ a b c Sleisenger, edited by Mark Feldman, Lawrence S. Friedman, Lawrence J. Brandt; consulting editor, Marvin H. (2009). Sleisenger & Fordtran's gastrointestinal and liver disease pathophysiology, diagnosis, management (9th ed.). St. Louis, Mo.: MD Consult. ISBN 978-1-4160-6189-2. {{cite book}}: |first= has generic name (help)CS1 maint: multiple names: authors list (link)
  3. ^ Elayat AA, el-Naggar MM, Tahir M (1995). "An immunocytochemical and morphometric study of the rat pancreatic islets". Journal of Anatomy. 186. (Pt 3) (Pt 3): 629–37. PMC 1167020. PMID 7559135.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ^ a b Brissova M, Fowler MJ, Nicholson WE, Chu A, Hirshberg B, Harlan DM, Powers AC (2005). "Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy". Journal of Histochemistry and Cytochemistry. 53 (9): 1087–97. doi:10.1369/jhc.5C6684.2005. PMID 15923354.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  5. ^ Ichii H, Inverardi L, Pileggi A, Molano RD, Cabrera O, Caicedo A, Messinger S, Kuroda Y, Berggren PO, Ricordi C (2005). "A novel method for the assessment of cellular composition and beta-cell viability in human islet preparations". American Journal of Transplantation. 5 (7): 1635–45. doi:10.1111/j.1600-6143.2005.00913.x. PMID 15943621.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  6. ^ a b Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, Caicedo A (2006). "The unique cytoarchitecture of human pancreatic islets has implications for islet cell function". Proceedings of the National Academy of Sciences of the United States of America. 103 (7): 2334–9. doi:10.1073/pnas.0510790103. ISSN 1091-6490. PMC 1413730. PMID 16461897.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  7. ^ Wang, Michael B.; Bullock, John; Boyle, Joseph R. (2001). Physiology. Hagerstown, MD: Lippincott Williams & Wilkins. p. 391. ISBN 0-683-30603-0.{{cite book}}: CS1 maint: multiple names: authors list (link)
  8. ^ Pérez-Armendariz M, Roy C, Spray DC, Bennett MV (1991). "Biophysical properties of gap junctions between freshly dispersed pairs of mouse pancreatic beta cells". Biophysical Journal. 59 (1): 76–92. doi:10.1016/S0006-3495(91)82200-7. PMC 1281120. PMID 2015391.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  9. ^ Meloche RM (2007). "Transplantation for the treatment of type 1 diabetes". World Journal of Gastroenterology. 13 (47): 6347–55. doi:10.3748/wjg.13.6347. PMID 18081223.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  10. ^ a b Hogan A, Pileggi A, Ricordi C (2008). "Transplantation: current developments and future directions; the future of clinical islet transplantation as a cure for diabetes". Frontiers of Bioscience. 13 (13): 1192–205. doi:10.2741/2755. PMID 17981623.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  11. ^ Chatenoud L (2008). "Chemical immunosuppression in islet transplantation—friend or foe?". New England Journal of Medicine. 358 (11): 1192–3. doi:10.1056/NEJMcibr0708067. ISSN 0028-4793. PMID 18337609.
  12. ^ Pileggi A, Cobianchi L, Inverardi L, Ricordi C (2006). "Overcoming the challenges now limiting islet transplantation: a sequential, integrated approach". Annals of the New York Academy of Sciences. 1079 (1): 383–98. doi:10.1196/annals.1375.059. ISSN 0077-8923. PMID 17130583.{{cite journal}}: CS1 maint: multiple names: authors list (link)

External links

Template:Endocrine pancreas

Retrieved from "https://en.wikipedia.org/w/index.php?title=Pancreatic_islets&oldid=488858722"